Arizona Health Sciences

Neuropathic plasticity in the opioid and non-opioid actions of dynorphin A fragments and their interactions with bradykinin B2 receptors on neuronal activity in the rat spinal cord.

TitleNeuropathic plasticity in the opioid and non-opioid actions of dynorphin A fragments and their interactions with bradykinin B2 receptors on neuronal activity in the rat spinal cord.
Publication TypeJournal Article
Year of Publication2014
AuthorsBannister K, Lee YSun, Goncalves L, Porreca F, Lai J, Dickenson AH
JournalNeuropharmacology
Volume85
Pagination375-83
Date Published2014 Oct
ISSN1873-7064
KeywordsAnalgesics, Non-Narcotic, Animals, Bradykinin B2 Receptor Antagonists, Disease Models, Animal, Dynorphins, Male, Neuralgia, Neuronal Plasticity, Neurons, Nociception, Peptide Fragments, Physical Stimulation, Rats, Sprague-Dawley, Serotonin 5-HT3 Receptor Agonists, Spinal Cord, Spinal Nerves
Abstract

Dynorphin A is an endogenous opioid peptide derived from the precursor prodynorphin. The proteolytic fragment dynorphin A (1-17) exhibits inhibitory effects via opioid receptors. Paradoxically, the activity of the dynorphin system increases with chronic pain and neuropathy is associated with the up-regulation of dynorphin biosynthesis. Dynorphin A (1-17) is cleaved in vivo to produce a non-opioid fragment, dynorphin A (2-17). Previously, a mechanism by which the non-opioid fragment promotes pain through agonist action at bradykinin receptors was revealed. Bradykinin receptor expression is up-regulated after nerve injury and both a truncated version of non-opioid fragment dynorphin A (2-17), referred to as 'Ligand 10', and novel bradykinin receptor antagonist 'Ligand 14', are known to bind to the bradykinin receptor. Here we show that Ligand 10 facilitates the response of wide dynamic range (WDR) neurons to innocuous and noxious mechanical stimuli in neuropathic, but not naïve, animals, while Ligand 14 exhibits inhibitory effects in neuropathic animals only. Furthermore, we reveal an inhibitory effect of Ligand 14 in naïve animals by pre-dosing with either Ligand 10 or a 5-HT3 receptor agonist to reflect activation of descending excitatory drives. Thus remarkably, by mimicking pro-excitatory pharmacological changes that occur after nerve injury in a naïve animal, we induce a state whereby the inhibitory actions of Ligand 14 are now effective. Ultimately our data support an increasing number of studies that suggest that blocking spinal bradykinin receptors may have a therapeutic potential in chronic pain states, here, in particular, in neuropathic pain.

DOI10.1016/j.neuropharm.2014.06.005
Alternate JournalNeuropharmacology
PubMed ID24937046
PubMed Central IDPMC4873257
Grant ListP01 DA006284 / DA / NIDA NIH HHS / United States
R01 CA097360 / CA / NCI NIH HHS / United States
R01 DA013449 / DA / NIDA NIH HHS / United States
Faculty Member Reference: 
Yeon Sun Lee, Ph.D.
Frank Porreca, Ph.D.